Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10557040)

  • 1. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
    Corradini P; Ladetto M; Pileri A; Tarella C
    Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular remission and non-Hodgkin's lymphoma.
    Darby AJ; Johnson PW
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):549-62. PubMed ID: 12468405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
    Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
    Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of minimal residual disease in lymphoid malignancies.
    Brüggemann M; Pott C; Ritgen M; Kneba M
    Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Chase ML; Armand P
    Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD).
    Olsson K; Gerard CJ; Zehnder J; Jones C; Ramanathan R; Reading C; Hanania EG
    Leukemia; 1999 Nov; 13(11):1833-42. PubMed ID: 10557059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
    Zhou A; Shi Y; Feng F; Lu S; He X; Han X
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does MRD have a role in the management of iNHL?
    Giudice ID; Starza ID; Foà R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease in non-Hodgkin's lymphoma.
    Schultze JL; Gribben JG
    Biomed Pharmacother; 1996; 50(9):451-8. PubMed ID: 8991117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring disease in lymphoma and CLL patients using molecular techniques.
    Gribben JG
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):179-95. PubMed ID: 11987923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.
    Garg S; Kumar A; Gupta R
    Clin Transl Oncol; 2021 Nov; 23(11):2206-2219. PubMed ID: 33991328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
    Drandi D; Ferrero S; Ladetto M
    Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical importance of semi-quantitative monitoring of lymphomas using the comparative polymerase chain reaction].
    Slavícková A; Ivánek R; Cerný J; Sálková J; Trnĕný M
    Cas Lek Cesk; 2002 Nov; 141(23):735-8. PubMed ID: 12650030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and relevance of minimal disease in lymphomas.
    Sharp JG; Chan WC
    Cancer Metastasis Rev; 1999; 18(1):127-42. PubMed ID: 10505551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy.
    Morra E
    Int J Biol Markers; 1999; 14(3):149-53. PubMed ID: 10569136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.
    Shimoni A; Nagler A; Kaplinsky C; Reichart M; Avigdor A; Hardan I; Yeshurun M; Daniely M; Zilberstein Y; Amariglio N; Brok-Simoni F; Rechavi G; Trakhtenbrot L
    Leukemia; 2002 Aug; 16(8):1413-8; discussion 1419-22. PubMed ID: 12145678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma.
    Hoogeveen-Westerveld M; Hupkes PE; Doekharan D; Dorssers LC; van't Veer MB; van Belzen N
    Leukemia; 1998 Nov; 12(11):1810-6. PubMed ID: 9823958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.